Lilly Halts Trials Of PPAR Alpha Agonist After Preclinical Safety Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II clinical trials of the atherosclerosis treatment candidate LY674 were halted after a primate study showed fatty liver deposits.